Dr. Tchekmedyian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
City of Hope Orange County Lennar Foundation Cancer Center
1000 FivePoint
Irvine, CA 92618Phone+1 949-333-7580Fax+1 949-333-7599
Education & Training
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2013 - 2016
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2010 - 2013
David Geffen School of Medicine at UCLAClass of 2010
Certifications & Licensure
CA State Medical License 2015 - 2025
FL State Medical License 2013 - 2017
MA State Medical License 2012 - 2015
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 2 citationsSafety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, ...Daniel J George, David R Spigel, Lucio N Gordan, Samith T Kochuparambil, Ana M Molina
BMJ Open. 2022-09-14 - 90 citationsPoziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 TrialXiuning Le, Robin Cornelissen, Marina Chiara Garassino, Jeffrey M. Clarke, Nishan Tchekmedyian
Journal of Clinical Oncology. 2021-11-29 - 42 citationsAn International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refr...Viola W. Zhu, Yen-Ting Lin, Dong Wan Kim, Herbert H. Loong, Misako Nagasaka
Journal of Thoracic Oncology. 2020-09-01
Press Mentions
Poziotinib Shows Promise in Hard-to-Treat NSCLC Exon 20 MutationsNovember 7th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
